Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Active not recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Ovarian Neoplasms 4Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 2Peritoneal Neoplasms 1

Interventions

Bevacizumab 35Paclitaxel 31Carboplatin 24pembrolizumab 23Specimen Handling 21Magnetic Resonance Spectroscopy 19Gemcitabine 18olaparib 16liposomal doxorubicin 16Cyclophosphamide 15fludarabine 12Topotecan 12Biopsy 12niraparib 11Cisplatin 10Taxes 8Nivolumab 8Immunoglobulin G 8Fulvestrant 8Disulfides 8Doxorubicin 7aldesleukin 6Surveys and Questionnaires 6palbociclib 5Oxaliplatin 5Fluorouracil 5trastuzumab deruxtecan 4oregovomab 4mirvetuximab soravtansine 4X-Rays 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Ovarian Neoplasms × oregovomab × 90 days × Clear all
NCT04938583 2026-04-06

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

CanariaBio Inc.

Phase 1/2 Active not recruiting
54 enrolled
Gynecologic

Ovarian Neoplasms

NCT05335993 2026-04-03

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

CanariaBio Inc.

Phase 2 Active not recruiting
10 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04498117 2026-04-01

FLORA-5

CanariaBio Inc.

Phase 3 Active not recruiting
615 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05605535 2026-04-01

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

CanariaBio Inc.

Phase 2 Active not recruiting
88 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡